Mechanism of microRNA in drug resistance in hepatocellular carcinoma

WANG Ling; XU Ximing

doi:10.14188/j.1671-8852.2023.0171

您当前的位置：

首页 >

文章列表页 >

Mechanism of microRNA in drug resistance in hepatocellular carcinoma

更新时间：2026-11-05

- Mechanism of microRNA in drug resistance in hepatocellular carcinoma
- Medical Journal of Wuhan University Vol. 46, Issue 5, Pages: 683-688(2025)
- 作者机构：
  
  武汉大学人民医院肿瘤内科湖北武汉 430060
- 作者简介：
- 基金信息：
- DOI：10.14188/j.1671-8852.2023.0171
  CLC： R735.7
- Received：16 March 2023，
  
  Published：25 May 2025
- 稿件说明：
移动端阅览
WANG Ling, XU Ximing. Mechanism of microRNA in drug resistance in hepatocellular carcinoma[J]. Medical Journal of Wuhan University, 2025, 46(5): 683-688.
DOI：

WANG Ling, XU Ximing. Mechanism of microRNA in drug resistance in hepatocellular carcinoma[J]. Medical Journal of Wuhan University, 2025, 46(5): 683-688. DOI： 10.14188/j.1671-8852.2023.0171.

摘要

肝细胞癌（HCC）是临床上十分常见的恶性肿瘤，随着全身化疗的应用，由化学药物耐药导致的患者预后不良也逐渐引起广泛重视。microRNA（miRNA）属于非编码RNA的一种，在肝细胞癌的发生发展中发挥重要作用。同时大量研究显示，miRNA也参与肝细胞癌化疗耐药的形成。本文通过分析和总结miRNA在肝癌耐药中涉及的相关机制作一综述，希望可以为未来靶向调控miRNA表达来逆转化疗耐药提供新的思路。

Abstract

Hepatocellular carcinoma（HCC）is a common clinical malignancy

with the use of systemic chemotherapy

the poor prognosis of patients due to chemoresistance is gaining widespread attention. microRNA（miRNA）

a type of non⁃coding RNA

plays an important role in the development of hepatocellular carcinoma. A large number of studies have shown that miRNAs are also involved in the formation of chemoresistance in HCC. In this paper

we analyze and summarize the mechanisms of miRNAs in drug resistance in HCC

and we hope to provide new ideas for targeting and regulating miRNA expression to reverse chemotherapy resistance in the future.

关键词

Keywords

references

SIEGEL R L , MILLER K D , FUCHS H E , et al . Cancer statistics, 2021 [J ] . CA Cancer J Clin , 2021 , 71 ( 1 ): 7 ⁃ 33 .

MCGLYNN K A , PETRICK J L , EL⁃SERAG H B . Epidemiology of hepatocellular carcinoma [J ] . Hepatology , 2021 , 73 ( Suppl 1 ): 4 ⁃ 13 .

FORNER A , REIG M , BRUIX J . Hepatocellular carcinoma [J ] . Lancet , 2018 , 391 ( 10127 ): 1301 ⁃ 1314 .

SI W , SHEN J , ZHENG H , et al . The role and mechanisms of action of micrornas in cancer drug resistance [J ] . Clin Epigenetics , 2019 , 11 ( 1 ): 25 .

CHEN X P , WANG Q , GUAN J , et al . Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells [J ] . World J Gastroenterol , 2006 , 12 ( 21 ): 3332 ⁃ 3337 .

HUANG W C , HSIEH Y L , HUNG C M , et al . BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib [J ] . PLoS One , 2013 , 8 ( 12 ): e83627 .

LI Y , WU A , CHEN L , et al . Hsa_circ_0000098 is a novel therapeutic target that promotes hepatocellular carcinoma development and resistance to doxorubicin [J ] . J Exp Clin Cancer Res , 2022 , 41 ( 1 ): 267 .

KONG J , QIU Y , LI Y , et al . TGF⁃β1 elevates P⁃gp and BCRP in hepatocellular carcinoma through HOTAIR/miR⁃145 axis [J ] . Biopharm Drug Dispos , 2019 , 40 ( 2 ): 70 ⁃ 80 .

LI T T , MOU J , PAN Y J , et al . MicroRNA⁃138⁃1⁃3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β⁃catenin/ABCB1 signaling pathway [J ] . J Biomed Sci , 2021 , 28 ( 1 ): 56 .

PU B , YU X , CAO Y , et al . miR⁃381 reverses multidrug resistance by negative regulation of the CTNNB1/ABCB1 pathway in HepG2/Dox cells, and the diagnostic and prognostic values of CTNNB1/ABCB1 are identified in patients with LIHC [J ] . DNA Cell Biol , 2021 , 40 ( 12 ): 1584 ⁃ 1596 .

KODAMA T , NEWBERG J Y , KODAMA M , et al . Transposon mutagenesis identifies genes and cellular processes driving epithelial⁃mesenchymal transition in hepatocellular carcinoma [J ] . Proc Natl Acad S ci USA , 2016 , 113 ( 24 ): E3384 ⁃E3393.

XU T , ZHANG J , CHEN W , et al . ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial⁃mesenchymal transition [J ] . Cancer Lett , 2016 , 377 ( 2 ): 140 ⁃ 148 .

YU Y , WANG Y , XIAO X , et al . MiR⁃204 inhibits hepatocellular cancer drug resistance and metastasis through targeting NUAK1 [J ] . Biochem Cell Biol , 2019 , 97 ( 5 ): 563 ⁃ 570 .

BAO Y , ZHANG Y , LU Y , et al . Overexpression of microRNA⁃9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2⁃mediated epithelial⁃mesenchymal transition [J ] . Int J Biol Sci , 2020 , 16 ( 5 ): 827 ⁃ 837 .

LONG L , XIANG H , LIU J , et al . ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells [J ] . Exp Mol Pathol , 2019 , 106 : 116 ⁃ 122 .

HIRAO A , SATO Y , TANAKA H , et al . MiR⁃125b⁃5p is involved in sorafenib resistance through ataxin⁃1⁃mediated epithelial⁃mesenchymal transition in hepatocellular carcinoma [J ] . Cancers (Basel) , 2021 , 13 ( 19 ): 4917 .

ENKHNARAN B , ZHANG G C , ZHANG N P , et al . MicroRNA⁃106b⁃5p promotes cell growth and sensitizes chemosensitivity to sorafenib by targeting the BTG3/Bcl⁃xL/p27 signaling pathway in hepatocellular carcinoma [J ] . J Oncol , 2022 , 2022 : 1971559 .

SHAO Y Y , CHEN P S , LIN L I , et al . Low miR⁃10b⁃3p associated with sorafenib resistance in hepatocellular carcinoma [J ] . Br J Cancer , 2022 , 126 ( 12 ): 1806 ⁃ 1814 .

LI H , GAI L , WU Z , et al . Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR⁃142⁃5p in hepatocellular carcinoma [J ] . Mol Biol Rep , 2022 , 49 ( 4 ): 3015 ⁃ 3024 .

YU J , ZHANG L . No PUMA, no death: Implications for p53⁃dependent apoptosis [J ] . Cancer Cell , 2003 , 4 ( 4 ): 248 ⁃ 249 .

FERNÁNDEZ⁃TUSSY P , RODRÍGUEZ⁃AGUDO R , FERNÁNDEZ⁃RAMOS D , et al . Anti⁃miR⁃518d⁃5p overcomes liver tumor cell death resistance through mitochondrial activity [J ] . Cell Death Dis , 2021 , 12 ( 6 ): 555 .

CHENG Z , NI Q , QIN L , et al . MicroRNA⁃92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling [J ] . Braz J Med Biol Res , 2021 , 54 ( 9 ): e10390 .

DONG Z B , WU H M , HE Y C , et al . MiRNA⁃124⁃3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1 [J ] . Cell Death Dis , 2022 , 13 ( 1 ): 35 .

RUAN Y , CHEN T , ZHENG L , et al . cDCBLD2 mediates sorafenib resistance in hepatocellular carcinoma by sponging miR⁃345⁃5p binding to the TOP2A coding sequence [J ] . Int J Biol Sci , 2023 , 19 ( 14 ): 4608 ⁃ 4626 .

CHEN M Y , YADAV V K , CHU Y C , et al . Hydroxychloroquine (HCQ) modulates autophagy and oxidative DNA damage stress in hepatocellular carcinoma to overcome sorafenib resistance via TLR9/SOD1/hsa⁃miR⁃30a⁃5p/beclin⁃1 axis [J ] . Cancers (Basel) , 2021 , 13 ( 13 ): 3227 .

XU W P , LIU J P , FENG J F , et al . MiR⁃541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy [J ] . Gut , 2020 , 69 ( 7 ): 1309 ⁃ 1321 .

JIN F , WANG Y , LI M , et al . MiR⁃26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy [J ] . Cell Death Dis , 2017 , 8 ( 1 ): e2540 .

LU Y , CHAN Y T , TAN H Y , et al . Epigenetic regulation of ferroptosis via ETS1/miR⁃23a⁃3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma [J ] . J Exp Clin Cancer Res , 2022 , 41 ( 1 ): 3 .

LUNT S Y , VANDER HEIDEN M G . Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation [J ] . Annu Rev Cell Dev Biol , 2011 , 27 : 441 ⁃ 464 .

ZHANG Z , TAN X , LUO J , et al . The miR⁃30a⁃5p/clcf1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma [J ] . Cell Death Dis , 2020 , 11 ( 10 ): 902 .

BERGAMINI C , LEONI I , RIZZARDI N , et al . MiR⁃494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma [J ] . J Exp Clin Cancer Res , 2023 , 42 ( 1 ): 145 .

XUE F , LIN X , CAI Z , et al . Doxifluridine⁃based pharmacosomes delivering miR⁃122 as tumor microenvironments⁃activated nanoplatforms for synergistic treatment of hepatocellular carcinoma [J ] . Colloids Surf B Biointerfaces , 2021 , 197 : 111367 .

XIAO L , HOU Y , HE H , et al . A novel targeted delivery system for drug⁃resistant hepatocellular carcinoma therapy [J ] . Nanoscale , 2020 , 12 ( 32 ): 17029 ⁃ 17044 .

LOU G , SONG X , YANG F , et al . Exosomes derived from miR⁃122⁃modified adipose tissue⁃derived mscs increase chemosensitivity of hepatocellular carcinoma [J ] . J Hematol Oncol , 2015 , 8 : 122 .

LOU G , CHEN L , XIA C , et al . MiR⁃199a⁃modified exosomes from adipose tissue⁃derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mtor pathway [J ] . J Exp Clin Cancer Res , 2020 , 39 ( 1 ): 4 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Identification of novel microRNA markers for hepatocellular carcinoma and their prognostic value

A case report of liver transplantation combined with atrial‑caval thrombectomy for the treatment of complex hepatocellular carcinoma

Expression analysis and prognostic value of ASPM gene in hepatocellular carcinoma

Preparation of methylene blue‐loaded nanoparticles and a preliminary study of photodynamic anti‐Trichophyton rubrum effect in vitro

Exploring the differences between CASIA2 and Pentacam in preoperative evaluation of cataracts: A comparison based on measurements of anterior chamber volume, corneal thickness, and pupil diameter

Related Author

WANG Ling

XU Ximing

CHEN Wenliang

XU Yangtao

CHEN Jiayu

LIU Xin

HU Xinyao

SHEN Yang

Related Institution

Cancer Center, Renmin Hospital of Wuhan University

NHC Key Laboratory of Translational Research on Transplantation Medicine & The 3rd Xiangya Hospital of Central South University

Zhongnan Hospital of Wuhan University; Institute of Hepatobiliary Diseases of Wuhan University & Transplant Center of Wuhan University

National Quality Control Center for Donated Organ Procurement; Hubei Key Laboratory of Medical Technology on Transplantation & Hubei Provincial Clinical Research Center for Natural Polymer Biological Liver

Clinical Laboratory, Renmin Hospital of Wuhan University

AI问答

⁰